Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation

Fig. 1

Lymphocyte subpopulaltions of our patient. A:CD19 + IgD + CD27– naïve B (94.2%), CD19 + IgD–CD27+ memory B (1.9%); B:CD38 + CD24+ transitional B (0%), CD38 + CD24– plasmablast B (1.7%); C: CD3 + CD4+ T (24.4%); CD3 + CD8+ T (66.3%); CD3 + CD4–CD8– double negative T (7.2%); D:subpopulaltions of CD4+ T cells: CD3 + CD4 + CD45RA + CD27+ naïve T (11%), CD3 + CD4 + CD45RO + CD27+ central memory T (49.6%), CD3 + CD4 + CD45RO + CD27– effector memory T (23.8%); E:subpopulaltions of CD8 + T cells: CD3 + CD8 + CD45RA + CD27+ naïve T (48.1%), CD3 + CD8 + CD45RO + CD27+ central memory T (13.7%), CD3 + CD8 + CD45RO + CD27– effect memory T (9.3%), CD3 + CD8 + CD45RA + CD27– TEMRA T (28.9%)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us